Longitudinal Multi-Domain Cognitive Assessment of Anti-Amyloid Monoclonal Antibodies Versus Acetylcholinesterase Inhibitors in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis - PubMed
5 hours ago
- #Alzheimer's disease
- #cognitive assessment
- #meta-analysis
- Anti-amyloid monoclonal antibodies (mAbs) showed consistent and statistically significant improvements on ADAS-Cog and MMSE compared to placebo, with relatively low heterogeneity in effects over time.
- Acetylcholinesterase inhibitors (AChEIs) demonstrated modest, heterogeneous, and sometimes non-significant effects on cognitive measures (ADAS-Cog, MMSE, CDR-SB), with effects appearing to attenuate with longer follow-up.
- The meta-analysis included 7 trials (n=8010) for mAbs and 9 trials (n=4993) for AChEIs in patients with mild cognitive impairment or mild Alzheimer's disease, focusing on longitudinal changes in ADAS-Cog, MMSE, and CDR-SB.
- mAbs exhibited moderate heterogeneity on CDR-SB (I2=56%), while AChEIs showed minimal heterogeneity on CDR-SB (I2=0%) but high heterogeneity on ADAS-Cog (I2=76%).
- Findings suggest mAbs may offer more consistent cognitive benefits in early Alzheimer's disease than AChEIs, but results should be interpreted cautiously due to study limitations.